This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Reply to Modafinil: Mischaracterization

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: The background research to support the claims of Drs. Kruszewski and Klotz begins and ends with the manufacturer’s package insert. However, the manufacturer’s package insert is neither a standard of care nor the most comprehensive and upto-date review of the preclinical or clinical science about a molecule. Were that so, new knowledge or findings would never be able to be conveyed to the field until the company or the U.S. Food and Drug Administration (FDA) determined to alter the manufacturer’s package insert.’ ‹


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 68

Quick Links: Psychiatry